An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial

International Journal of Cardiology

Volumn 241, Issue , 2017, Pages 277-282

  Hanberg, Jennifer S ^a   Tang, W H Wilson ^b   Wilson, F Perry ^a   Coca, Steven G ^c   Ahmad, Tariq ^a   Brisco, Meredith A ^d   Testani, Jeffrey M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute heart failure; Loop diuretics; Outcomes

Indexed keywords

LOOP DIURETIC AGENT; FUROSEMIDE;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE EXACERBATION; DIURESIS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EMERGENCY CARE; FEMALE; FLUID BALANCE; FLUID OUTPUT; HEART FAILURE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FUROSEMIDE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PATIENT READMISSION; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME;

EID: 85017185668     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.03.114     Document Type: Article

References (39)

1. Giamouzis, G., Kalogeropoulos, A., Georgiopoulou, V., Laskar, S., Smith, A.L., Dunbar, S., Triposkiadis, F., Butler, J., Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J. Card. Fail. 17:1 (2011), 54–75.
2. Fonarow, G.C., Corday, E., Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail. Rev. 9:3 (2004), 179–185.
3. Bradley, S.M., Levy, W.C., Veenstra, D.L., Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis. Circ. Cardiovasc. Qual. Outcomes 2:6 (2009), 566–573.
4. Gheorghiade, M., Filippatos, G., De Luca, L., Burnett, J., Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am. J. Med. 119:12 Suppl 1 (2006), S3–S10.
5. Gheorghiade, M., Follath, F., Ponikowski, P., Barsuk, J.H., Blair, J.E., Cleland, J.G., Dickstein, K., Drazner, M.H., Fonarow, G.C., Jaarsma, T., Jondeau, G., Sendon, J.L., Mebazaa, A., Metra, M., Nieminen, M., Pang, P.S., Seferovic, P., Stevenson, L.W., van Veldhuisen, D.J., Zannad, F., Anker, S.D., Rhodes, A., JJ, McMurray, Filippatos, G., Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur. J. Heart Fail. 12:5 (2010), 423–433.
6. Gheorghiade, M., Pang, P.S., Acute heart failure syndromes. J. Am. Coll. Cardiol. 53:7 (2009), 557–573.
7. Gheorghiade, M., Vaduganathan, M., Fonarow, G.C., Bonow, R.O., Rehospitalization for heart failure: problems and perspectives. J. Am. Coll. Cardiol., 2012.
8. Testani, J.M., Chen, J., McCauley, B.D., Kimmel, S.E., Shannon, R.P., Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122:3 (2010), 265–272.
9. Testani, J.M., Brisco, M.A., Chen, J., McCauley, B.D., Parikh, C.R., Tang, W.H., Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J. Am. Coll. Cardiol. 62:6 (2013), 516–524.
10. van der Meer, P., Postmus, D., Ponikowski, P., Cleland, J.G., O'Connor, C.M., Cotter, G., Metra, M., Davison, B.A., Givertz, M.M., Mansoor, G.A., Teerlink, J.R., Massie, B.M., Hillege, H.L., Voors, A.A., The predictive value of short term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J. Am. Coll. Cardiol., 2013.
11. Greene, S.J., Gheorghiade, M., Vaduganathan, M., Ambrosy, A.P., Mentz, R.J., Subacius, H., Maggioni, A.P., Nodari, S., Konstam, M.A., Butler, J., Filippatos, G., Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur. J. Heart Fail. 15:12 (2013), 1401–1411.
12. Neuberg, G.W., Miller, A.B., O'Connor, C.M., Belkin, R.N., Carson, P.E., Cropp, A.B., Frid, D.J., Nye, R.G., Pressler, M.L., Wertheimer, J.H., Packer, M., Diuretic resistance predicts mortality in patients with advanced heart failure. Am. Heart J. 144:1 (2002), 31–38.
13. Eshaghian, S., Horwich, T.B., Fonarow, G.C., Relation of loop diuretic dose to mortality in advanced heart failure. Am. J. Cardiol. 97:12 (2006), 1759–1764.
14. Felker, G.M., Mentz, R.J., Diuretics and ultrafiltration in acute decompensated heart failure. J. Am. Coll. Cardiol. 59:24 (2012), 2145–2153.
15. Francis, G.S., Siegel, R.M., Goldsmith, S.R., Olivari, M.T., Levine, T.B., Cohn, J.N., Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann. Intern. Med. 103:1 (1985), 1–6.
16. Testani, J.M., Cappola, T.P., Brensinger, C.M., Shannon, R.P., Kimmel, S.E., Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J. Am. Coll. Cardiol. 58:4 (2011), 375–382.
17. Mascha, E.J., Dalton, J.E., Kurz, A., Saager, L., Statistical grand rounds: understanding the mechanism: mediation analysis in randomized and nonrandomized studies. Anesth. Analg. 117:4 (2013), 980–994.
18. Emsley, R., Dunn, G., White, I.R., Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat. Methods Med. Res. 19:3 (2010), 237–270.
19. Richiardi, L., Bellocco, R., Zugna, D., Mediation analysis in epidemiology: methods, interpretation and bias. Int. J. Epidemiol. 42:5 (2013), 1511–1519.
20. Baron, R.M., Kenny, D.A., The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 51:6 (1986), 1173–1182.
21. Bohm, M., Swedberg, K., Komajda, M., Borer, J.S., Ford, I., Dubost-Brama, A., Lerebours, G., Tavazzi, L., Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:9744 (2010), 886–894.
22. Vergeer, M., Bots, M.L., van Leuven, S.I., Basart, D.C., Sijbrands, E.J., Evans, G.W., Grobbee, D.E., Visseren, F.L., Stalenhoef, A.F., Stroes, E.S., Kastelein, J.J., Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118:24 (2008), 2515–2522.
23. Felker, G.M., Lee, K.L., Bull, D.A., Redfield, M.M., Stevenson, L.W., Goldsmith, S.R., LeWinter, M.M., Deswal, A., Rouleau, J.L., Ofili, E.O., Anstrom, K.J., Hernandez, A.F., McNulty, S.E., Velazquez, E.J., Kfoury, A.G., Chen, H.H., Givertz, M.M., Semigran, M.J., Bart, B.A., Mascette, A.M., Braunwald, E., O'Connor, C.M., Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364:9 (2011), 797–805.
24. Felker, G.M., O'Connor, C.M., Braunwald, E., Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circ. Heart Fail. 2:1 (2009), 56–62.
25. Brater, D.C., Day, B., Burdette, A., Anderson, S., Bumetanide and furosemide in heart failure. Kidney Int. 26:2 (1984), 183–189.
26. Vargo, D.L., Kramer, W.G., Black, P.K., Smith, W.B., Serpas, T., Brater, D.C., Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharmacol. Ther. 57:6 (1995), 601–609.
27. Brenner, B.M., Rector, F.C., Brenner & Rector's the kidney. 2008, Saunders Elsevier, Philadelphia.
28. Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F. III, Feldman, H.I., Kusek, J.W., Eggers, P., Van Lente, F., Greene, T., Coresh, J., A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150:9 (2009), 604–612.
29. Mickey, R.M., Greenland, S., The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 129:1 (1989), 125–137.
30. Tuck, M.L., Sambhi, M.P., Kramer, S.B., Eggena, P., Barrett, J., Enhanced renin levels after discontinuation of furosemide: additional effects of loop diuretics on renin release. Clin. Exp. Hypertens. A 4:8 (1982), 1359–1375.
31. Kaissling, B., Bachmann, S., Kriz, W., Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am. J. Phys. 248:3 Pt 2 (1985), F374–F381.
32. Mulder, H., Schopman, W. Jr., van der Lely, A.J., Schopman, W. Sr., Acute changes in plasma renin activity, plasma aldosterone concentration and plasma electrolyte concentrations following furosemide administration in patients with congestive heart failure—interrelationships and diuretic response. Horm. Metab. Res. 19:2 (1987), 80–83.
33. Ellison, D.H., Velazquez, H., Wright, F.S., Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J. Clin. Invest. 83:1 (1989), 113–126.
34. Gottlieb, S.S., Skettino, S.L., Wolff, A., Beckman, E., Fisher, M.L., Freudenberger, R., Gladwell, T., Marshall, J., Cines, M., Bennett, D., Liittschwager, E.B., Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol. 35:1 (2000), 56–59.
35. Abdallah, J.G., Schrier, R.W., Edelstein, C., Jennings, S.D., Wyse, B., Ellison, D.H., Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J. Am. Soc. Nephrol. 12:7 (2001), 1335–1341.
36. Chen, H.H., Redfield, M.M., Nordstrom, L.J., Cataliotti, A., Burnett, J.C. Jr., Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am. J. Physiol. Ren. Physiol. 284:5 (2003), F1115–F1119.
37. McCurley, J.M., Hanlon, S.U., Wei, S.K., Wedam, E.F., Michalski, M., Haigney, M.C., Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J. Am. Coll. Cardiol. 44:6 (2004), 1301–1307.
38. Castrop, H., Schiessl, I.M., Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2). Am. J. Physiol. Ren. Physiol. 307:9 (2014), F991–F1002.
39. Mentz, R.J., Stevens, S.R., DeVore, A.D., Lala, A., Vader, J.M., AbouEzzeddine, O.F., Khazanie, P., Redfield, M.M., Stevenson, L.W., O'Connor, C.M., Goldsmith, S.R., Bart, B.A., Anstrom, K.J., Hernandez, A.F., Braunwald, E., Felker, G.M., Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. JACC Heart Fail. 3:2 (2015), 97–107.